Skip to main content

Table 5 Healthcare resource utilization outcomes in the subsequent period by FVC% change group

From: Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

By lung-function decline category (based on relative change in FVC%)a
  Stable [A] Marginal [B] Significant [C] Relative effect measure (95 % CI)
  (N = 250) (N = 98) (N = 142) [C] vs. [A] [C] vs. [B] [B] vs. [A]
  12-Month IR per Patient IRR
Rate of IPF-related outpatient visits 2.24 2.57 2.55 1.14 (0.89–1.46) 0.99 (0.76–1.30) 1.15 (0.91–1.45)
 Unscheduled and/or urgent care 0.18 0.38 0.54 3.01 (1.51–5.97) 1.41 (0.78–2.55) 2.13 (1.05–4.34)
 For a suspected AEx 0.19 0.33 0.54 2.81 (1.47–5.40) 1.64 (0.86–3.11) 1.72 (0.80–3.69)
Rate of outpatient visits indicating that the following medications/treatments were prescribed for IPF
 Prednisone 1.06 1.16 1.60 1.51 (1.08–2.10) 1.38 (1.02–1.86) 1.10 (0.79–1.52)
 Azathioprine 0.36 0.31 0.54 1.51 (0.78–2.93) 1.72 (0.84–3.53) 0.88 (0.44–1.76)
 N-acetylcysteine 0.65 0.70 0.79 1.22 (0.79–1.89) 1.13 (0.67–1.90) 1.08 (0.69–1.70)
Rate of outpatient visits that included the following tests/procedures
 Arterial blood gas test 0.17 0.23 0.34 2.04 (0.77–5.38) 1.46 (0.53–4.03) 1.40 (0.55–3.56)
 HRCT 0.23 0.35 0.35 1.55 (0.74–3.21) 1.02 (0.45–2.31) 1.51 (0.76–2.99)
 Chest X-ray 0.48 0.66 0.60 1.23 (0.75–2.02) 0.90 (0.55–1.48) 1.36 (0.84–2.20)
 Lung biopsy 0.03 0.04 0.01 0.44 (0.02–8.70) 0.31 (0.02–4.91) 1.42 (0.13–15.70)
 Pulmonary rehabilitation 0.18 0.19 0.26 1.44 (0.79–2.63) 1.35 (0.58–3.11) 1.07 (0.52–2.23)
Rate of IFP-related ER visits 0.35 0.54 0.53 1.53 (0.71–3.28) 0.98 (0.51–1.87) 1.56 (0.66–3.71)
 For a suspected AEx 0.13 0.22 0.29 2.22 (0.95–5.21) 1.32 (0.60–2.87) 1.69 (0.67–4.27)
Rate of ER visits that included the following tests/procedures
 Arterial blood gas test 0.15 0.35 0.33 2.24 (1.01–4.99) 0.95 (0.45–2.00) 2.36 (1.01–5.49)
 HRCT 0.09 0.18 0.20 2.17 (0.85–5.58) 1.09 (0.37–3.22) 1.99 (0.60–6.67)
 Chest X-ray 0.20 0.28 0.30 1.51 (0.69–3.32) 1.10 (0.55–2.21) 1.37 (0.61–3.09)
 Supplemental oxygen therapy 0.17 0.23 0.29 1.74 (0.73–4.14) 1.26 (0.52–3.04) 1.39 (0.46–4.20)
Rate of IPF-related hospitalizations 0.24 0.32 0.61 2.53 (0.70–9.10) 1.89 (0.94–3.78) 1.34 (0.34–5.29)
 For a suspected AEx 0.09 0.21 0.43 4.69 (1.84–11.99) 2.05 (1.03–4.08) 2.29 (0.82–6.35)
 Rate of hospital days 1.13 2.32 5.25 4.63 (1.31–16.42) 2.27 (0.86–5.97) 2.05 (0.66–6.33)
 Rate of ICU stays 0.05 0.17 0.26 4.95 (1.20–20.41) 1.53 (0.59–3.99) 3.23 (0.72–14.53)
 Rate of ICU days 0.30 0.69 1.22 4.05 (0.79–20.91) 1.75 (0.58–5.35) 2.31 (0.54–9.83)
Rate of hospitalizations that included the following tests/procedures
 Arterial blood gas test 0.10 0.19 0.35 3.58 (1.33–9.64) 1.87 (0.73–4.80) 1.92 (0.61–6.00)
 Mechanical ventilation 0.04 0.11 0.14 3.29 (0.63–17.23) 1.33 (0.38–4.70) 2.47 (0.57–10.73)
 Non-invasive ventilation 0.02 0.08 0.22 10.17 (3.25–31.86) 2.80 (1.05–7.51) 3.63 (0.90–14.70)
 Supplemental oxygen therapy 0.07 0.13 0.28 3.95 (1.38–11.29) 2.11 (0.93–4.82) 1.87 (0.62–5.66)
  12-Month Risk OR
Risk of having ≥1 outpatient visit 97.5 % 97.3 % 95.0 % 0.48 (0.14–1.62) 0.52 (0.12–2.20) 0.93 (0.23–3.76)
 Unscheduled or urgent care 11.4 % 26.9 % 34.5 % 4.10 (1.95–8.63) 1.43 (0.69–2.98) 2.87 (1.39–5.92)
 For a suspected AEx 12.7 % 21.9 % 33.8 % 3.52 (1.62–7.67) 1.82 (0.82–4.05) 1.93 (0.90–4.15)
Risk of having ≥1 ER visit 14.4 % 29.4 % 32.4 % 2.85 (1.36–5.98) 1.15 (0.53–2.52) 2.47 (1.22–5.03)
 For a suspected AEx 7.8 % 16.7 % 22.1 % 3.33 (1.40–7.94) 1.42 (0.57–3.54) 2.35 (0.98–5.65)
Risk of having ≥1 hospitalizations 7.8 % 19.1 % 30.0 % 5.04 (2.13–11.93) 1.82 (0.71–4.66) 2.76 (1.14–6.70)
 Intensive care unit (ICU) stay 2.4 % 8.4 % 12.4 % 5.86 (1.43–24.01) 1.56 (0.41–5.90) 3.77 (0.88–16.03)
 For a suspected AEx 5.9 % 15.1 % 27.8 % 6.08 (2.45–15.07) 2.16 (0.84–5.54) 2.81 (1.10–7.20)
  1. IR incidence rate, IRR incidence rate ratio, OR odds ratio
  2. aLung-function change categories were defined as the relative change in FVC% from index to approximately 6 months following IPF diagnosis. "Stable" was defined as decline <5 %. "Marginal" was defined as decline ≥5 % and <10 %, while "Significant" was defined as decline ≥10 %